Given the potential activating effects of BRAF inhibition in the presence of oncogenic NRAS, and the potential for mutations in downstream pathway members such as MEK1 [44], it may become important to assess genetic heterogeneity among tumor specimens both before treatment and upon disease recurrence to more fully understand the development of resistance to targeted therapies. Here, NRAS is linked to neoplasm.